NCT01845584View on ClinicalTrials.gov

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

NPB-01

Trial Locations (1)

Unknown

Japan, Osaka

Sponsors
All Listed Sponsors
lead

Nihon Pharmaceutical Co., Ltd

INDUSTRY

NCT01845584 - Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. | Biotech Hunter | Biotech Hunter